Physician Assistant Perspectives: When to Consider Tazemetostat in R/R FL
May 28th 2025A panelist discusses how tazemetostat offers a convenient, mutation-independent oral option for third-line follicular lymphoma treatment, balancing efficacy and tolerability while addressing patient lifestyle and financial considerations in an era of advanced therapies like CAR T-cell and bispecific antibodies.
Insights From The NAPOLI-3 and PRODIGE4 Trials In Metastatic Pancreatic Adenocarcinoma
May 28th 2025Panelists discuss how the NAPOLI-3 trial led to FDA approval of NALIRIFOX after demonstrating superior median overall survival (11.1 months) and progression-free survival (7.4 months) compared to gemcitabine/nab-paclitaxel, with key differences from the older PRODIGE 4 study including a lower oxaliplatin dose that may reduce side effects.
First-Line Treatment Options for Metastatic Pancreatic Adenocarcinoma
May 28th 2025Panelists discuss how the current first-line treatment landscape for metastatic pancreatic adenocarcinoma includes NCCN-recommended regimens like FOLFIRINOX, gemcitabine plus nab-paclitaxel, and the newest addition NALIRIFOX, with treatment selection guided by toxicity profiles, patient-specific factors, and the importance of germline testing.
Combination Immunotherapy Strategies in Melanoma: Insights From Key Trials
May 23rd 2025Panelists discuss how 2 key clinical trials, Checkmate 067 and RELATIVITY-047, established the efficacy of different immunotherapy combinations while highlighting the significant difference in toxicity profiles between ipilimumab plus nivolumab (60% grade 3/4 toxicity) versus relatlimab plus nivolumab (19% grade 3/4 toxicity).
Clinical Perspectives: Single-Agent Vs Combination Immunotherapy for Melanoma
May 23rd 2025Panelists discuss how monotherapy may still be appropriate for certain patient populations including those with desmoplastic melanoma, solid organ transplants, severe autoimmune disease, and older patients where the toxicity risk of combination therapy may outweigh benefits.
Neurological Toxicity Recognition: ICANS Assessment and Management
May 22nd 2025Panelists discuss how the assessment and management of immune effector cell–associated neurotoxicity syndrome involves grading symptoms from mild to life-threatening, emphasizing the need for prompt recognition and rapid intervention to prevent progression and minimize long-term neurological damage.
Essential Patient and Caregiver Education for Tarlatamab Treatment Success
May 22nd 2025Panelists discuss how education materials for tarlatamab include detailed treatment overviews, potential adverse effects, and monitoring requirements, while emphasizing the importance of ensuring that patients and caregivers fully understand the information and can recognize early signs of adverse reactions.
Looking Ahead in R/R FL: Unmet Needs and What’s Next
May 21st 2025Panelists discuss how unmet needs in relapsed/refractory follicular lymphoma (R/R FL), including durability of responses, adverse effect management, personalized treatment, resistance to therapy, and access to care, are driving exciting developments in emerging targeted therapies, improved CAR T technologies, combination approaches, and efforts to enhance access and affordability for patients.
Collaborating With Community Providers in Treating Patients With Complex R/R FL
May 21st 2025Panelists discuss how collaborating with community physicians and providers through clear communication, shared care plans, education, referral networks, and regular monitoring is crucial for treating patients with complex cancer and ensuring coordinated care, particularly for those receiving advanced therapies such as CAR T and bispecific antibodies.